Efficacy and safety of rituximab combined with CHOP or combined with dose fractionated CHOP in the treatment of primary gastric diffuse large B cell lymphoma / 中华肿瘤杂志

<p><b>OBJECTIVE</b>The aim of this study was to compare the safety and efficacy profiles of R-CHOP and R-fCHOP regimes in the treatment of primary gastric diffuse large B cell lymphoma (PG-DLBCL).</p><p><b>METHODS</b>Data of PG-DLBCL patients admitted in our hospital from March 2010 to March 2014 were collected retrospectively. Differences in gastrointestinal bleeding and perforation between the R-CHOP group and R-fCHOP group were compared. The influence of the gastrointestinal complication on subsequent treatment was also analyzed. Treatment outcome of the two groups was also compared.</p><p><b>RESULTS</b>A total of 50 patients were included in this retrospective study. Forty of them were in the R-CHOP group, another ten were in the R-fCHOP group. Patients in the R-fCHOP group had a higher rate of Lugano late stage disease, and a relatively high rate of a deeper/larger ulcer. Fence occult blood test (FOBT) was positive in one (10.0%) patient in the R-fCHOP group, and 11 (31.4%) patients in the R-CHOP group, among them one had hematemesis and had to give up the subsequent chemotherapy. No perforation was observed in both groups. The response rate (RR) was 92.5% in the R-CHOP group and 90.0% in the R-fCHOP group (P > 0.05). The PFS was also comparable between the two groups (P > 0.05).</p><p><b>CONCLUSIONS</b>R-fCHOP regimen has a good safety profile in patients with Lugano late stage and deep/large ulcers, who are of high risk of gastrointestinal bleeding or perforation, and also has a comparable efficacy profile when compared with the R-CHOP regimen in short-term follow-up.</p>

A phase II multicenter study to investigate R-ICE as a salvage therapy for relapsed diffuse large B-cell lymphoma / 中华血液学杂志

<p><b>OBJECTIVE</b>To investigate the efficacy and safety of rituximab together with etoposide, carboplatin, and ifosfamide (R-ICE) as a salvage therapy for relapsed diffuse large B-cell lymphoma (DLBCL) after treatment with rituximab based first-line chemotherapy (R-Chemo).</p><p><b>METHODS</b>DLBCL patients with complete remission (CR) or complete remission unconfirmed (CRu) after 6-8 cycles of R-Chemo treatment but relapsed for first time after stopping treatment were included in this study. Three cycles of R-ICE regimen were given to the patients [1st day: rituximab, 375 mg/m²; 2nd-4th day: ifosfamide, 1 600 mg/m²; 3rd day: carboplatin, area under the curve (AUC) =5 (maximum dosage: 800 mg), 2nd-4th day: etoposide, 100 mg/m²]. The primary endpoint was overall response rate (ORR). The secondary endpoints were the 2-year progression-free survival (PFS), 2-year overall survival (OS), and toxicity.</p><p><b>RESULTS</b>Thirty-two patients with median age at 55(range: 26-68) were recruited in this clinical study and the final analysis. After three cycles of R-ICE salvage treatment, 16 patients (50.0%) achieved CR or CRu and 9 patients (28.1 %) achieved partial remission (PR). The ORR was 78.1%. The 2-year PFS and OS were 40.8% and 60.7%, respectively. Nineteen patients (59.4%) had 3/4 grade adverse events. The ratios of leukopenia neutropenia, anemia and thrombocytopenia in patients with 3/4 grades were 37.5%, 15.6%, and 37.5%, respectively. No patient died.</p><p><b>CONCLUSION</b>R-ICE is an effective salvage therapy for R-Chemo relapsed DLBCL with manageable toxicities.</p>

Endocrine system disturb induced by antineoplastic agents / 中国癌症杂志

Effects of antineoplastic agents on endocrine system are common, but it is difficult to identify since clinical complaints are subtle, and even more difficult to relate a particular chemotherapeutic regimen to the induced endocrine disturb. This review was organized according to the pattern of endocrine system diseases induced by antineoplastic agents, such as disorders of glucose metabolism, free water clearance, mineral metabolism, lipid metabolism and GH secretion and growth, metabolic bone diseases, adrenal dysfunction, thyroid disorders and reproductive dysfunction. Early detection and treatment of endocrine deficiency may have a significant impact on the quality and duration of life in a cancer survivor.

Clinical characteristic and current status of treatment for nasal NK/T cell lymphoma / 中国癌症杂志

Nasal NK/T cell lymphoma is a rare type of lymphoma. There is no universal standard for the diagnoses and the treatment of the disease. Our paper summarized the epidemiology, etiology, clinical features, stage, pathology, diagnoses, treatment and prognoses of Nasal NK/T cell lymphoma in order to give some clarification in coping with the disease.

Iressa for refractory non-small cell lung cancer: A preliminary report / 中国肺癌杂志

<p><b>BACKGROUND</b>To summarize the preliminary experience on Iressa for refractory non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Fifty-five patients with NSCLC, who failed after surgery, radiotherapy, chemotherapy or combination of the above modalities, were registered in this clinical trail. Prior to Iressa, 50 patients were in stage IV, and 5 in stage III. Iressa was administered orally at 250 mg, once a day until cancer progressed or severe toxicity occured, which made patients intolerable. The median time for administration of Iressa was 4 months.</p><p><b>RESULTS</b>The toxicity of Iressa was tolerable with 47% of skin toxicity (rash) and 2%-7% of diarrhea, nausea, orally mucosal ulceration and alopecia. Overall response rate was 20%. Different sites of distant metastases responded to Iressa in different ways with higher response rate for pulmonary disseminations. One quarter of patients felt improvement of their symptoms over 2 weeks. Median survival time for entire group was 5 months (1-17 months). Median time to progression (TTP) was 3.6 months. Survival at 6 months was 67%. Prognostic predictor, which could imply the outcome, was skin toxicity with higher response rate and longer survival time ( P < 0.05), and no relationship with sex, histological types of NSCLC and distant metastasis had been found.</p><p><b>CONCLUSIONS</b>Iressa could be tolerated by refractory NSCLC patients with acceptable side-effects, and have palliative effects.</p>

Advances in chemotherapy for upper gastrointestinal tumors / 中国癌症杂志

The aim of this review is to evaluate the recent advances in chemotherapy for upper gastrointestinal tumors (esophagus,stomach,pancreas,liver).The role of both the neoadjuvant,adjuvant and palliative chemotherapy regimens, efficacy and side effects will be discussed,as well as its future development.

Progress of the relationship between cyclooxygenase-2 and breast cancer / 中国癌症杂志

Recent researches indicated that cyclooxygena se -2 (COX-2) expression was related not only to development of breast cancer but also to clinicopathological parameters and prognosis of advanced breast cancer. The preclinical and clinical studies on the use of selective COX-2 inhibitors f or the prevention and treatment of breast cancer have become the focus of invest igation.

Phase Ⅱ clinical trial on docetaxel in the treatment of non-small-cell lung cancer / 中国癌症杂志

Purpose:To investigate the efficacy and safety of docetaxel and two docetaxel plus cisplatin regimens in patients with non-small-cell lung cancer (NSCLC).Methods:Patients with NSCLC were randomly assigned to receive single-agent docetaxel (AISU) every 3 weeks (A);docetaxel (AISU) 75 mg/m 2 plus cisplatin 75 mg/m 2 every 3 weeks (B);docetaxel (Taxotere) 75 mg/m 2 plus cisplatin 75 mg/m 2 every 3 weeks (C). Results:104 of 115 patients were evaluable for efficacy. Overall response rates of A,B and C were 8.10%,23.53% and 27.27%, respectively. Response with B was similar to C. The major toxicities were neutropenia,anemia,febrile neutropenia,fever,alopecia,nausea,vomiting and fatigue. Neutropenia was more common with C than with B ( P

Advances in dendritic cells vaccines / 中国癌症杂志

Dendritic cells are now given more attention th ese years in tumor immuno-therapy. In this review, we summarized the advances o f dendritic cells vaccines and their applications in malignant tumors such as me lanoma and renal carcinoma.